Changes in Beneficial Ownership · 4
Applied Therapeutics Inc.
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2025-12-19
- Issuer
- Applied Therapeutics, Inc.
- Issuer CIK
- 0001697532
- Trading symbol
- APLT
- No longer subject to Section 16
- Checked
Reporting owner 1
- Name
- Hooks Corwin Dale
- Reporting owner CIK
- 0001665347
- Relationship
- Officer
- Officer title
- Chief Commercial Officer
- Address
- C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2025-12-19 | A · Form 4[F1] | 312,500 | A | 0 | 868,253[F2] | D |
| Common Stock | 2026-02-03 | D · Form 4[F3][F4] | 862,500 | D | [F3][F4] | 5,753 | D |
| Common Stock | 2026-02-03 | U · Form 4[F3][F5] | 5,753 | D | [F5] | 0 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
- D · Form 4
- Disposition to the issuer under Rule 16b-3(e)
- U · Form 4
- Shares tendered in a change of control
Footnotes
- F1
- Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date.↩ 1
- F2
- The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the understatement of the total holdings.↩ 1
- F3
- Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").↩ 1↩ 2↩ 3
Signature 1
- Signed
- /s/ Leslie D. Funtleyder, as attorney-in-fact
- Date
- 2026-02-03
Company context
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG).